Bristol Myers Squibb's Breyanzi Receives European Commission Marketing Authorization

 Bristol Myers Squibb Co. said the European Commission has approved marketing authorization for Breyanzi, a lymphoma treatment.

The marketing authorization is based on results from a study evaluating Breyanzi in adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, including those with a range of histologies and high-risk disease.

The marketing authorization is applicable in all European Union member states.

https://www.marketscreener.com/quote/stock/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-s-Breyanzi-Receives-European-Commission-Marketing-Authorization-39971617/